Argenx announces closing of global offering

Regulated information – inside i nformation july 24, 2023, 4 : 30 pm et july 24, 2023, 10 : 30 pm cet amsterdam, the netherlands — argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced today the closing of its previously announced global offering of an aggregate of 2,581,633 ordinary shares, which may be represented by american depositary shares (“adss”) and which includes full exercise of the underwriters' option to purchase 336,734 additional ordinary shares in the form of adss. the gross proceeds from the global offering were approximately $1.27 billion (approximately €1.13 billion).
ARGX Ratings Summary
ARGX Quant Ranking